Sarepta Therapeutics (NYSE: SRPT) will submit a New Drug Application for its Duchenne muscular dystrophy treatment eteplirsen but the stock price plunged $8.75 to close at $37.68.
Sarepta Plunges Despite NDA Submission
July 24, 2013 at 16:31 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
| ||||||